Skip to main content
. 2015 Jun 22;5:11198. doi: 10.1038/srep11198

Figure 3. ctDNA and LDH level monitoring for patient 5 with corresponding radiological findings.

Figure 3

(a) Patient 5’s ctDNA level fell following treatment (CheckMate 067 trial; anti-PD-1 antibody nivolumab alone versus anti-CTLA-4 antibody ipilimumab alone versus combination of the two). The CT scans also showed disease regression with (b) red arrow points to lung metastasis on day 1 of treatment and (c) the corresponding site on day 263 with no evidence of disease. PET scan performed on day 188 showed no metabolically active lesions (Fig. 3a).